Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
This article was originally published in The Pink Sheet Daily
Executive Summary
Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.